Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance.

× No keyword cloud information.

10 in total

1. Immunotherapy in indolent Non-Hodgkin's Lymphoma.

Authors: Ghid Amhaz; Ali Bazarbachi; Jean El-Cheikh
Journal: Leuk Res Rep Date: 2022-05-18

Review 2. Treatment of indolent lymphoma.

Authors: Seong Hyun Jeong
Journal: Blood Res Date: 2022-04-30

Review 3. Use of anti-CD20 therapy in follicular and marginal zone lymphoma: a review of the literature.

Authors: Luis Miguel Juárez-Salcedo; Diego Conde-Royo; Keina Quiroz-Cervantes; Samir Dalia
Journal: Drugs Context Date: 2020-05-06

4. Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study.

Authors: Sung Yong Oh; Won Seog Kim; Jin Seok Kim; Seok Jin Kim; Dok Hyun Yoon; Deok-Hwan Yang; Won Sik Lee; Hyo Jung Kim; Ho-Young Yhim; Seong Hyun Jeong; Jong Ho Won; Suee Lee; Jee Hyun Kong; Sung-Nam Lim; Jun Ho Ji; Kyung A Kwon; Gyeong-Won Lee; Jae Hoon Lee; Ho Sup Lee; Ho-Jin Shin; Cheolwon Suh
Journal: Cancer Commun (Lond) Date: 2019-10-16

5. Splenic Marginal Zone Lymphoma with Prominent Myelofibrosis Mimicking Triple-Negative Primary Myelofibrosis.

Authors: Miyuki Tsutsui; Hajime Yasuda; Yasunori Ota; Norio Komatsu
Journal: Case Rep Oncol Date: 2019-11-01

Review 6. How we treat mature B-cell neoplasms (indolent B-cell lymphomas).

Authors: Melissa Lumish; Lorenzo Falchi; Brandon S Imber; Michael Scordo; Gottfried von Keudell; Erel Joffe
Journal: J Hematol Oncol Date: 2021-01-06 Impact factor: 17.388

7. Marginal zone lymphoma: present status and future perspectives.

Authors: Chan Y Cheah; Emanuele Zucca; Davide Rossi; Thomas M Habermann
Journal: Haematologica Date: 2022-01-01 Impact factor: 9.941

8. Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial.

Authors: Michael Herold; Eva Hoster; Ann Janssens; Helen McCarthy; Alessandra Tedeschi; Chris Pocock; Andras Rosta; Marek Trněný; Tina G Nielsen; Andrea Knapp; Wolfgang Hiddemann; Robert Marcus
Journal: Hemasphere Date: 2022-02-24

9. Risk adapted approach: How to treat splenic marginal zone lymphoma in resource-poor settings? - The real-life experience of a Brazilian cancer treatment center.

Authors: Luís Alberto de Pádua Covas Lage; Felipe Faganelli Caboclo Dos Santos; Débora Levy; Frederico Rafael Moreira; Samuel Campanelli Freitas Couto; Hebert Fabrício Culler; Renata de Oliveira Costa; Vanderson Rocha; Juliana Pereira
Journal: BMC Cancer Date: 2020-08-03 Impact factor: 4.430

10. Aggressive variant of splenic marginal zone lymphoma characterized using a cancer panel test and treated with rituximab-containing chemotherapy: A case report.

Authors: Kazuya Ishiguro; Yasushi Sasaki; Yoshitake Takagi; Takeshi Niinuma; Hiromu Suzuki; Takashi Tokino; Toshiaki Hayashi; Tohru Takahashi; Tetsuyuki Igarashi; Yoshihiro Matsuno
Journal: Medicine (Baltimore) Date: 2020-08-28 Impact factor: 1.817

10 in total